Stephen K. Brannan - Nov 1, 2021 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol
KRTX
Transactions as of
Nov 1, 2021
Transactions value $
-$1,000,256
Form type
4
Date filed
11/3/2021, 04:17 PM
Next filing
Dec 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $13.6K +2.5K +16.67% $5.45* 17.5K Nov 1, 2021 Direct
transaction KRTX Common Stock Options Exercise $749 +103 +0.59% $7.27* 17.6K Nov 1, 2021 Direct
transaction KRTX Common Stock Sale -$14.1K -103 -0.59% $136.67 17.5K Nov 1, 2021 Direct F1
transaction KRTX Common Stock Options Exercise $41.6K +7.63K +43.57% $5.45* 25.1K Nov 1, 2021 Direct
transaction KRTX Common Stock Sale -$1.04M -7.63K -30.35% $136.67 17.5K Nov 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -2.5K -4.25% $0.00 56.3K Nov 1, 2021 Common Stock 2.5K $5.45 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -103 -0.21% $0.00 48K Nov 1, 2021 Common Stock 103 $7.27 Direct F3
transaction KRTX Option (right to buy) Options Exercise $0 -7.63K -13.54% $0.00 48.7K Nov 1, 2021 Common Stock 7.63K $5.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2021.
F2 This option vests as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3 This option vested as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.